Disease management
The collaboration addresses delays in diagnosis and treatment by leveraging AI to help ensure patients with prostate and breast cancer are identified and treated more promptly.
The company will use the funds to support a 510(k) submission to the FDA for its Flexi-Port SLF-TANL for oncology patients.
Also, fellow Korean medical AI companies have obtained regulatory approvals across global markets.
The company plans to offer an aggregate of 7.9 million shares of its common stock with an initial public offering price between $18 and $20 per share.
The model could be deployed as a decision support tool in emergency departments.
The funds will be used to help the company expand into the employer and health plan markets and speed up the development of its AI technology for providers and members.
The company began trading on the NYSE today under the ticker symbol HNGE, opening at $39.25, up 23% from its IPO price of $32, and closing at $37.56 per share.
MedStar Health and Abundant Venture Partners co-developed the model.
The AI-powered COPD care coordination tool uses EHR data and natural language processing to identify and manage high-risk patients.
The organization is seeking feedback on how to best advance digital health to empower seniors using technology, while reducing administrative burdens and improving interoperability.